Wegovy is a prescription medication used for weight management in adults with obesity or overweight. It is a long-acting form of the hormone glucagon-like peptide-1 (GLP-1) and works by reducing appetite and increasing feelings of fullness [3].
According to Drug Patent Watch [1], Wegovy's patent will expire in 2039, which suggests that it can be used long-term. However, the expiration of the patent does not necessarily mean that the medication will be safe and effective for long-term use.
As for the safety and effectiveness of Wegovy, it has been approved by the U.S. Food and Drug Administration (FDA) for long-term use [2]. The medication has undergone clinical trials and has been found to be safe and effective in helping individuals with obesity or overweight lose weight and maintain weight loss [3]. However, like any medication, it may cause side effects, such as nausea, vomiting, diarrhea, and constipation [2].
It is important to note that Wegovy is not a standalone treatment for obesity or overweight. It should be used in combination with a reduced-calorie diet and increased physical activity [2]. Additionally, it is not recommended for use in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3].
In conclusion, Wegovy can be used long-term as its patent is set to expire in 2039. It has been approved by the FDA for long-term use and has been found to be safe and effective in helping individuals with obesity or overweight lose weight and maintain weight loss. However, like any medication, it may cause side effects, and it should be used in combination with a reduced-calorie diet and increased physical activity. Individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Wegovy.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.today.com/health/diet-fitness/is-wegovy-safe-for-weight-loss-rcna67277
[3] https://www.health.harvard.edu/blog/a-new-treatment-for-obesity-202109102589